Want to see IDYA full AI Analyst Report?
IDEAYA Biosciences (IDYA) Stock Forecast & Price Target
689 Followers
IDYA Analyst Ratings
Strong Buy
11Buy0Hold0Sell
Based on 11 analysts giving stock ratings to IDEAYA Biosciences in the past 3 months
IDYA Stock 12 Month Forecast
Average Price Target
$53.40▲(74.23% Upside)Based on 11 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $53.40 with a high forecast of $66.00 and a low forecast of $44.00. The average price target represents a 74.23% change from the last price of $30.65.
Past 12 Months12 Month ForecastJan2026Oct2026
High$66.00
Average$53.40
Low$44.00
Highest Price TargetHighest$66.00Average Price Target$53.40Lowest Price TargetLowest$44.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Yigal Nochomovitz | Citi | $65→$66 | buy | 115.33%Upside | Reiterated | 11/05/26 | ||
| Robert Driscoll | Wedbush | $60→$63 | buy | 105.55%Upside | Reiterated | 11/04/26 | ||
| Gregory Renza | Truist Financial | $59→$57 | buy | 85.97%Upside | Reiterated | 11/03/26 | ||
| Paul Jeng | Guggenheim | $57→$52 | buy | 69.66%Upside | Reiterated | 11/03/26 | ||
| Leonid Timashev | RBC Capital | $48→$45 | buy | 46.82%Upside | Assigned | 11/03/26 | ||
| Graig Suvannavejh | Mizuho Securities | $50→$44 | buy | 43.56%Upside | Reiterated | 10/29/26 | ||
| Laura Prendergast | Stifel Nicolaus | $48 | buy | 56.61%Upside | Reiterated | 10/26/26 | ||
| Anupam Rama | J.P. Morgan | ― | buy | ― | Reiterated | 10/26/26 | ||
| Michael Yee | UBS | $50 | buy | 63.13%Upside | Reiterated | 10/26/26 | ||
| Sharon Zackfia | William Blair | $51 | buy | 66.39%Upside | Initiated | 10/15/26 | ||
| Charles Zhu | LifeSci Capital | $58 | buy | 89.23%Upside | Reiterated | 09/27/26 | ||
| Silvan Turkcan | Citizens JMP | $45→$42 | buy | 37.03%Upside | Reiterated | 08/06/26 | ||
| Eva Fortea Verdejo | Wells Fargo | $48 | buy | 56.61%Upside | Reiterated | 08/05/26 | ||
| Corinne Johnson | Goldman Sachs | $35→$36 | hold | 17.46%Upside | Reiterated | 06/03/26 | ||
| Tyler Van Buren | TD Cowen | ― | buy | ― | Reiterated | 05/05/26 |
| Rating | Follow | Article | |||
|---|---|---|---|---|---|
| Yigal NochomovitzCiti | BuyReiterated$65→$66 | 11/05/26 | 115.33%Upside | ||
| Robert DriscollWedbush | BuyReiterated$60→$63 | 11/04/26 | 105.55%Upside | ||
| Gregory RenzaTruist Financial | BuyReiterated$59→$57 | 11/03/26 | 85.97%Upside | ||
| Paul JengGuggenheim | BuyReiterated$57→$52 | 11/03/26 | 69.66%Upside | ||
| Leonid TimashevRBC Capital | BuyAssigned$48→$45 | 11/03/26 | 46.82%Upside | ||
| Graig SuvannavejhMizuho Securities | BuyReiterated$50→$44 | 10/29/26 | 43.56%Upside | ||
| Laura PrendergastStifel Nicolaus | BuyReiterated$48 | 10/26/26 | 56.61%Upside | ||
| Anupam RamaJ.P. Morgan | BuyReiterated | 10/26/26 | ― | ||
| Michael YeeUBS | BuyReiterated$50 | 10/26/26 | 63.13%Upside | ||
| Sharon ZackfiaWilliam Blair | BuyInitiated$51 | 10/15/26 | 66.39%Upside | ||
| Charles ZhuLifeSci Capital | BuyReiterated$58 | 09/27/26 | 89.23%Upside | ||
| Silvan TurkcanCitizens JMP | BuyReiterated$45→$42 | 08/06/26 | 37.03%Upside | ||
| Eva Fortea VerdejoWells Fargo | BuyReiterated$48 | 08/05/26 | 56.61%Upside | ||
| Corinne JohnsonGoldman Sachs | HoldReiterated$35→$36 | 06/03/26 | 17.46%Upside | ||
| Tyler Van BurenTD Cowen | BuyReiterated | 05/05/26 | ― |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering IDEAYA Biosciences
3 Months
Success Rate18/31 ratings generated profit
58%
Average Return
+9.26%
Copying Charles Zhu's trades and holding each position for 3 Months would result in 58.06% of your transactions generating a profit, with an average return of +9.26% per trade.
1 Year
Success Rate21/31 ratings generated profit
68%
Average Return
+32.62%
Copying Charles Zhu's trades and holding each position for 1 Year would result in 67.74% of your transactions generating a profit, with an average return of +32.62% per trade.
2 Years
Success Rate22/31 ratings generated profit
71%
Average Return
+30.99%
Copying Charles Zhu's trades and holding each position for 2 Years would result in 70.97% of your transactions generating a profit, with an average return of +30.99% per trade.
IDYA Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 16 | 17 | 13 | 15 | 12 |
| Buy | 4 | 11 | 13 | 17 | 10 |
| Hold | 2 | 2 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 22 | 30 | 26 | 32 | 22 |
In the current month, IDYA has received 22 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 53.40.
IDYA Financial Forecast
High$-0.83
Consensus$-1.18
Low$-1.47
IDYA Earnings Forecast
Next quarter’s earnings estimate for IDYA is -$1.18 with a range of -$1.47 to -$0.83. The previous quarter’s EPS was -$1.22. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$50M
Consensus$18.8M
Low$0.00
IDYA Sales Forecast
Next quarter’s sales forecast for IDYA is $18.77M with a range of $0 to $50.00M. The previous quarter’s sales results were $10.24M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
IDYA Stock Forecast FAQ
What is IDYA’s average 12-month price target, according to analysts?
Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is $53.40.
What is IDYA’s upside potential, based on the analysts’ average price target?
IDEAYA Biosciences has 74.23% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is IDYA a Buy, Sell or Hold?
IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
What is IDEAYA Biosciences’s price target?
The average price target for IDEAYA Biosciences is $53.40. This is based on 11 12-month price targets, issued in the past 3 months. The highest analyst price target is $66.00, the lowest forecast is $44.00. The average price target represents a 74.23% increase from the current price of $30.65.
What do analysts say about IDEAYA Biosciences?
IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Street analysts.
How can I buy shares of IDYA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
